We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Targeting Cannabinoid CB2 Receptors in the CNS
News

Targeting Cannabinoid CB2 Receptors in the CNS

Targeting Cannabinoid CB2 Receptors in the CNS
News

Targeting Cannabinoid CB2 Receptors in the CNS

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Targeting Cannabinoid CB2 Receptors in the CNS"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Abstract
Endocannabinoids activate two types of specific G-protein coupled receptors (GPCRs), namely cannabinoid CB1 and CB2. Contrary to the psychotropic actions of agonists of CB1 receptors, and serious side effects of the selective antagonists of this receptor, drugs acting on CB2 receptors appear as promising drugs to combat CNS diseases (Parkinson’s disease, Huntington’s chorea, cerebellarataxia, amyotrohiclateralsclerosis). Differential localization of CB2 receptors in neural cell types and up regulation in neuroinflammation are keys to understand the therapeutic potential in inter alia diseases that imply progressive neurodegeneration. Medicinal chemistry approaches are now engaged to develop imaging tools to map receptors in the living human brain, to develop more efficacious agonists, and to investigate the possibility to develop allosteric modulators.

The full article, Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders, is published in Frontiers in Neuroscience and can be accessed free of charge. 

Advertisement